FDA OKs Phase 1 Trial of Nasal Spray Immunotherapy Protollin

I-Mab will launch a Phase 1 clinical trial evaluating Protollin, its nasal spray immunotherapy candidate for Alzheimer’s disease. The biotech company’s announcement follows the recent approval of an investigational new drug (IND) application for Protollin by the U.S. Food and Drug Administration (FDA). “Advancing Protollin into clinic is a critical milestone in the search to develop novel therapies for this devastating disease, and we are honored to be engaging in a planning process with partners…

You must be logged in to read/download the full post.

The post FDA OKs Phase 1 Trial of Nasal Spray Immunotherapy Protollin appeared first on BioNewsFeeds.